Tetraiodothyroacetic acid and transthyretin silencing inhibit pro-metastatic effect of L-thyroxin in anoikis-resistant prostate cancer cells through regulation of MAPK/ERK pathway.
Tetraiodothyroacetic acid and transthyretin silencing inhibit pro-metastatic effect of L-thyroxin in anoikis-resistant prostate cancer cells through regulation of MAPK/ERK pathway.
复制标题
DOI：
10.1016/j.yexcr.2016.08.019
复制
发表时间：
2016-10
影响因子：
3.7
通讯作者：
Peng Zhang;Lifeng Chen;Yarong Song;Xuechao Li;Yadong Sun;Yajun Xiao;Y. Xing
中科院分区：
文献类型：
--
作者：
Peng Zhang;Lifeng Chen;Yarong Song;Xuechao Li;Yadong Sun;Yajun Xiao;Y. Xing
Prostate cancer is one of the most common malignancies in adult males and metastasis is the leading cause of death cases without satisfactory treatment options. Anoikis-resistance and migration are crucial aspects for the metastasis of various human cancer cells including prostate cancer andL-thyroxin (T4) has been proved to play vital roles in tumor metastasis. The present study demonstrated that T4promoted migration and depressed detachment-induced apoptosis in anoikis-resistant prostate cancer cells while tetraiodothyroacetic acid (tetrac), a competitive antagonist of T4at integrin αvβ3, reversed T4induced effects through diminishing expressions of XIAP, MMP-2, VEGF together with inhibited activity of MAPK/ERK pathway. In addition, we illustrated that over-expression of transthyretin (TTR) was positively correlated to the progression and metastatic potential in prostate cancer. Similar to tetrac, TTR silencing also inverted T4mediated bioeffects on anoikis-resistant PC-3 cells. The current study sheds light on novel therapeutic strategies for metastatic prostate cancer.ImplicationsThis study identified novel compound and target for preventing metastasis in anoikis-resistant prostate cancer cells, which might offer potential therapeutic alternatives for advanced prostate cancer.
